ArticleNucleic acids research2023
DrugMAP: molecular atlas and pharma-information of all drugs.
Article in Nucleic acids research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Computational Prediction of the Severity of Adverse Drug Reactions Caused by Drug-Drug Interactions.Pharmaceuticals (Basel, Switzerland) · 2026Article
- RadioPharm: the database of radiopharmaceuticals.Nucleic acids research · 2026Article
- Artificial Intelligence Revolution in Pharmaceutical Sciences : Advancements, Clinical Impacts, and Applications.Current pharmaceutical biotechnology · 2026Review
- Harnessing Single-Cell RNA-Seq for Computational Drug Repurposing in Cancer Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- HyperPhS: a pharmacophore-guided multimodal representation framework for metabolic stability prediction through contrastive hypergraph learning.Bioinformatics (Oxford, England) · 2025Article
- Heterogeneous network drug-target interaction prediction model based on graph wavelet transform and multi-level contrastive learning.Scientific reports · 2025Article
- ADME-drug-likeness: enriching molecular foundation models via pharmacokinetics-guided multi-task learning for drug-likeness prediction.Bioinformatics (Oxford, England) · 2025Article
- Scaffold and SAR studies on c-MET inhibitors using machine learning approaches.Journal of pharmaceutical analysis · 2025Article
- Predicting Epitopes of Synthetic Binding Proteins Using Protein Structure Prediction and Protein-Protein Docking.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Exploring the globoid cell leukodystrophy protein network and therapeutic interventions.Scientific reports · 2024Article
- DrugRepoBank: a comprehensive database and discovery platform for accelerating drug repositioning.Database : the journal of biological databases and curation · 2024Article
- Advancing drug-response prediction using multi-modal and -omics machine learning integration (MOMLIN): a case study on breast cancer clinical data.Briefings in bioinformatics · 2024Article
- FERREG: ferroptosis-based regulation of disease occurrence, progression and therapeutic response.Briefings in bioinformatics · 2024Article
- DDID: a comprehensive resource for visualization and analysis of diet-drug interactions.Briefings in bioinformatics · 2024Article
- CyclicPepedia: a knowledge base of natural and synthetic cyclic peptides.Briefings in bioinformatics · 2024Article
- Graph-pMHC: graph neural network approach to MHC class II peptide presentation and antibody immunogenicity.Briefings in bioinformatics · 2024Article
- VARIDT 3.0: the phenotypic and regulatory variability of drug transporter.Nucleic acids research · 2024Article
- INTEDE 2.0: the metabolic roadmap of drugs.Nucleic acids research · 2024Article
- SingPro: a knowledge base providing single-cell proteomic data.Nucleic acids research · 2024Article
- ADCdb: the database of antibody-drug conjugates.Nucleic acids research · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The efficacy and safety of drugs are widely known to be determined by their interactions with multiple molecules of pharmacological importance, and it is therefore essential to systematically depict the molecular atlas and pharma-information of studied drugs. However, our understanding of such information is neither comprehensive nor precise, which necessitates the construction of a new database providing a network containing a large number of drugs and their interacting molecules. Here, a new database describing the molecular atlas and pharma-information of drugs (DrugMAP) was therefore constructed. It provides a comprehensive list of interacting molecules for >30 000 drugs/drug candidates, gives the differential expression patterns for >5000 interacting molecules among different disease sites, ADME (absorption, distribution, metabolism and excretion)-relevant organs and physiological tissues, and weaves a comprehensive and precise network containing >200 000 interactions among drugs and molecules. With the great efforts made to clarify the complex mechanism underlying drug pharmacokinetics and pharmacodynamics and rapidly emerging interests in artificial intelligence (AI)-based network analyses, DrugMAP is expected to become an indispensable supplement to existing databases to facilitate drug discovery. It is now fully and freely accessible at: https://idrblab.org/drugmap/.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.